Dopamine D1 Rather than D2 Receptor Agonists Disrupt Prepulse Inhibition of Startle in Mice

被引:0
|
作者
Rebecca J Ralph-Williams
Virginia Lehmann-Masten
Mark A Geyer
机构
[1] Alcohol and Drug Abuse Research Center,Department of Psychiatry
[2] Harvard Medical School and McLean Hospital,undefined
[3] University of California,undefined
来源
Neuropsychopharmacology | 2003年 / 28卷
关键词
dopamine; prepulse inhibition; startle; mice; D1 receptor; D2 receptor;
D O I
暂无
中图分类号
学科分类号
摘要
Although substantial literature describes the modulation of prepulse inhibition (PPI) by dopamine (DA) in rats, few reports address the effects of dopaminergic manipulations on PPI in mice. We characterized the effects of subtype-specific DA agonists in the PPI paradigm to further delineate the specific influences of each DA receptor subtype on sensorimotor gating in mice. The mixed D1/D2 agonist apomorphine and the preferential D1-family agonists SKF82958 and dihydrexidine significantly disrupted PPI, with differing or no effects on startle. In contrast to findings in rats, the D2/D3 agonist quinpirole reduced startle but had no effect on PPI. Pergolide, which has affinity for D2/D3 and D1-like receptors, reduced both startle and PPI, but only at the higher, nonspecific doses. In addition, the D1-family receptor antagonist SCH23390 blocked the PPI-disruptive effects of apomorphine on PPI, but the D2-family receptor antagonist raclopride failed to alter the disruptive effect of apomorphine. These studies reveal potential species differences in the DA receptor modulation of PPI between rats and mice, where D1-family receptors may play a more prominent and independent role in the modulation of PPI in mice than in rats. Nevertheless, due to the limited selectivity of DA receptor agonists, further studies using specific receptor knockout mice are warranted to clarify the respective roles of specific DA receptor subtypes in modulating PPI in mice.
引用
收藏
页码:108 / 118
页数:10
相关论文
共 50 条
  • [31] DOPAMINE RECEPTOR SUBTYPES - BEYOND THE D1/D2 CLASSIFICATION
    ANDERSEN, PH
    GINGRICH, JA
    BATES, MD
    DEARRY, A
    FALARDEAU, P
    SENOGLES, SE
    CARON, MG
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) : 231 - 236
  • [32] D1 AND D2 DOPAMINE RECEPTOR MECHANISMS IN DOPAMINERGIC BEHAVIORS
    KOLLER, WC
    HERBSTER, G
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (03) : 221 - 231
  • [33] Constitutive activity of a chimeric D2/D1 dopamine receptor
    Kozell, LB
    Neve, KA
    MOLECULAR PHARMACOLOGY, 1997, 52 (06) : 1137 - 1149
  • [34] Adolescent Maturation of D1 and D2 Dopamine Receptor Interactions
    Dwyer, Jennifer Buenzle
    Martinez, Lesly
    Ganddini, Gabriela
    Perez, Mayra
    Leslie, Frances M.
    FASEB JOURNAL, 2010, 24
  • [35] D1/D2 DOPAMINE RECEPTOR INTERACTION AT THE BIOCHEMICAL LEVEL
    STRANGE, PG
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (02) : 48 - 49
  • [36] Evidence against dopamine D1/D2 receptor heteromers
    A L Frederick
    H Yano
    P Trifilieff
    H D Vishwasrao
    D Biezonski
    J Mészáros
    E Urizar
    D R Sibley
    C Kellendonk
    K C Sonntag
    D L Graham
    R J Colbran
    G D Stanwood
    J A Javitch
    Molecular Psychiatry, 2015, 20 : 1373 - 1385
  • [37] D2, but not D1 dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates
    Meschler, JP
    Clarkson, FA
    Mathews, PJ
    Howlett, AC
    Madras, BK
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2000, 292 (03): : 952 - 959
  • [38] Sensitivities of dopamine D1 and D2 receptor radioligands to changes in synaptic dopamine
    Gifford, AN
    Gatley, SJ
    Shea, C
    Ashby, CR
    Volkow, ND
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (05) : 927 - 927
  • [39] ANTIPARKINSONIAN ACTION OF GLUTAMATE ANTAGONISTS - INTERACTION WITH DOPAMINE D1 AND D2 AGONISTS
    KLOCKGETHER, T
    WULLNER, U
    EBLEN, F
    LOSCHMANN, PA
    ANNALS OF NEUROLOGY, 1995, 38 (02) : 329 - 329
  • [40] Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors
    Dall'Olio, R
    Gaggi, R
    Voltattorni, M
    Tanda, A
    Gandolf, O
    BEHAVIOURAL PHARMACOLOGY, 2002, 13 (08): : 633 - 638